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Abstract MicroRNAs (miRNAs), small non-coding RNAs, play a critical role in differentiation and self-renewal of pluripotent
stem cells, as well as in differentiation of cardiovascular lineage cells. Several miRNAs have been demonstrated to
repress stemness factors such as Oct4, Nanog, Sox2 and Klf4 in embryonic stem cells, thereby promoting embryonic
stem cell differentiation. Furthermore, targeting of different miRNAs promotes reprogramming towards induced
pluripotent stem cells. MicroRNAs are critical for vascular smooth muscle cell differentiation and phenotype regu-
lation, and miR-143 and miR-145 play a particularly important role in this respect. Notably, these miRNAs are
down-regulated in several cardiovascular disease states, such as in atherosclerotic lesions and vascular neointima for-
mation. MicroRNAs are critical regulators of endothelial cell differentiation and ischaemia-induced neovascularization.
miR-126 is important for vascular integrity, endothelial cell proliferation and neovascularization. miR-1 and miR-133
are highly expressed in cardiomyocytes and their precursors and regulate cardiomyogenesis. In addition, miR-499
promotes differentiation of cardiomyocyte progenitor cells. Notably, miRNA expression is altered in cardiovascular
disease states, and recent studies suggest that dysregulated miRNAs may limit cardiovascular repair responses. Dys-
regulation of miRNAs may lead to an altered function and differentiation of cardiovascular progenitor cells, which is
also likely to represent a limitation of autologous cell-based treatment approaches in these patients. These findings
suggest that targeting of specific miRNAs may represent an interesting novel opportunity to impact on endogenous
cardiovascular repair responses, including effects on stem/progenitor cell differentiation and functions. This approach
may also serve to optimize cell-based treatment approaches in patients with cardiovascular disease.
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This article is part of the Review Focus on: The Role of MicroRNA in Cardiovascular Biology and Disease
1. Introduction
MicroRNAs (miRNAs) are small, non-coding RNAs regulating gene
expression at the post-transcriptional level by mRNA degradation
or translational repression.1 The human genome has been estimated
to contain up to 1000 miRNAs.1 The regulation and processing of
miRNAs is still incompletely understood; however, important pro-
gress has been made in unravelling of these pathways over the past
few years. In the first part of this review article, we summarize
some recent insights into the biogenesis and processing of miRNAs
(see also Figure 1) that are also important for the discussion of
studies evaluating the role of miRNAs in stem/progenitor cell differen-
tiation and function.
Notably, miRNAs have been found to target transcription factors
critically regulating embryonic stem cell (ESC) self-renewal and
differentiation.2–5 In addition, several miRNAs have been shown to
facilitate reprogramming towards induced pluripotent stem cells
(iPSCs).6–10 Moreover, specific miRNAs have been identified to regu-
late differentiation and function of cardiac, vascular smooth muscle,
and endothelial progenitor cells, which are discussed in the present
article.
Furthermore, emerging data suggest that in cardiovascular disease
altered miRNA expression may limit and impair cardiovascular
repair responses, including differentiation and function of stem/pro-
genitor cells. Hence, understanding of the physiological and patho-
physiological regulation and role of miRNAs in stem and progenitor
cells will lead to an improved understanding of the pathophysiology
of cardiovascular disease and is likely to provide interesting novel po-
tential therapeutic targets to promote endogenous cardiovascular
repair processes.
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2. Biogenesis and processing of
miRNA
Most miRNAs are located within introns, and are processed from the
primary transcript of their host genes.11 This co-transcription of
miRNAs is thought to aid in the fine-tuning of biological processes
regulated by the host genes.12–14 miRNAs are mostly transcribed
by RNA polymerase II,15 which generates the primary transcript
with a stem–loop structure, called pri-miRNA (Figure 1).
Pri-miRNAs are further processed by the microprocessor, i.e. the
complex of the nuclear RNase III protein Drosha and the associated
co-factor DGCR8 (DiGeorge syndrome critical region 8), which
releases a shorter hairpin of about 65 nucleotides (pre-miRNA)
after cleavage.16,17 Pre-miRNAs are transported via exportin-5 from
the nucleus to the cytoplasm,18 where they are cleaved by Dicer,
an RNase III enzyme.19–23 One strand of the unwound miRNA
helix is preferentially chosen and loaded into the RNA-induced silen-
cing complex (RISC), whereas the other strand, miRNA*, is
degraded.24,25 In the RISC, miRNAs interact mainly with the 3′ un-
translated regions (UTRs) of mRNAs, leading to mRNA destabiliza-
tion or translational repression, or both.26 Recent data suggest that
in humans miRNAs largely lead to mRNA destabilization.27 Of note,
more recently miRNAs have also been suggested to increase
protein expression of some targets;28,29 however, the underlying
mechanisms need to be investigated further.
MicroRNA biogenesis may also differ from the above canonical
stepwise processing pathway. For example, mirtrons are very short
introns of genes that form pre-miRNAs directly, by splicing, and are
therefore not processed by Drosha.30,31 In addition, there are
miRNAs that are processed independent of Dicer that require the
Argonaute protein Ago2 for miRNA maturation.32,33
3. MicroRNAs regulate embryonic
stem cell differentiation and
self-renewal
3.1 Dicer and DGCR8 knockout inhibit ESC
differentiation
The contribution of miRNAs to differentiation and function of ESCs
has initially been elucidated using knockout models of parts of the
miRNA-processing pathways, i.e. deletion of Dicer or the Drosha co-
factor, DGCR8. Notably, Dicer deficiency was lethal at an early stage
of development in mouse embryos.34 In vitro, Dicer-null ESCs failed to
differentiate and remained in a self-renewal state, indicating a critical
role of miRNAs for ESC differentiation.35 Likewise, DGCR8-knockout
ESCs failed to undergo cell lineage commitment, and had an incom-
plete silencing of the pluripotency factors Oct4, Sox2, Nanog and
Rex1.36 These findings underscore the critical role of miRNAs for
ESC differentiation into specific cell lineages (Figure 2).
3.2 MicroRNAs regulating ESC
self-renewal and differentiation
Subsequently, several miRNAs have been observed to be expressed
preferentially in embryonic stem cells. By sequencing short RNAs,
the miRNA 290–295 cluster has been found to be highly expressed
in embryonic stem cells.2 These miRNAs promote ESC proliferation
by facilitating the G1 to S transition in the cell cycle,37,38 and are
therefore considered to have a role in maintaining ESC pluripotency
(Figure 2).
Several miRNAs have been shown to be part of the ESC differ-
entiation process and to repress multiple pluripotency factors
involved in self-renewal of ESCs, as described below. miR-134,
miR-296, and miR-470, which are up-regulated in the differentiation
of mouse embryonic stem cells, target the transcription factors
Nanog, Sox2, and Oct4.4 miR-21 suppresses self-renewal of
mouse ESCs, at least in part by decreasing expression of the plur-
ipotency factors Oct4, Nanog, Sox2, and c-Myc.3 miR-145 expres-
sion is low in self-renewing human ESCs and is highly
up-regulated during human ESC differentiation. miR-145 directly
targets the pluripotency factors Oct4, Sox2, and Klf4, and increased
Figure 1 Biogenesis of microRNA (miRNA). Schematic diagram of
the canonical pathway of miRNA transcription and processing.
miRNAs are transcribed mainly by RNA polymerase II, leading to
the primary transcript (pri-miRNA). In the nucleus, pri-miRNAs
are cleaved by the RNA-specific endoribonuclease Drosha (and its
cofactor DGCR8), resulting in the pre-miRNA. Exportin-5 trans-
ports the pre-miRNA into the cytoplasm. In the cytoplasm, pre-
miRNAs are processed by Dicer, leading to the miRNA–miRNA*
duplex, where the miRNA is the active component and miRNA*
gets degraded. In the RNA-induced silencing complex (RISC),
which contains a member of the Argonaute family, the miRNA
strand leads to mRNA destabilization or translational repression of
mRNA. Ago1-4, Argonaute 1-4.
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miR-145 expression inhibits ESC self-renewal, represses expression
of the above pluripotency genes, and induces lineage-restricted
differentiation.5
4. Targeting miRNAs to promote
reprogramming towards induced
pluripotent stem cells
Mouse fibroblasts were the first differentiated somatic cells to be
reprogrammed into iPSCs by viral transduction of Oct3/4, Sox2,
c-Myc, and Klf4.39 Human fibroblasts could subsequently be
converted into iPSCs by transduction of the same four transcription
factors40 or by introduction of Oct4, Sox2, Nanog, and Lin28.41 As
mentioned above, stemness factors are regulated by miRNAs,
which renders them highly interesting for promoting nuclear
reprogramming processes of somatic cells, given the advantage of
a non-viral transfection procedure. The role of miRNAs in promot-
ing reprogramming of iPSCs has therefore been intensely
examined.42
4.1 Enhancing transcription factor-induced
reprogramming towards iPSCs using
miRNAs
Notably, silencing of members of the let-7 miRNA family in murine
somatic cells has been shown to promote reprogramming towards
iPSCs.8 Introduction of miR-291-3p, miR-294, and miR-295, together
with the transcription factors Oct4, Sox2, and Klf4, substantially
enhanced the efficacy of reprogramming towards iPSCs.7 These
miRNAs have been termed embryonic stem cell-specific cell
cycle-regulating miRNAs (ESCCs) because of their abundance and
role in proliferation of mouse ESCs.37 Similar results have been
reported using the human ESCC miRNA orthologues miR-302b and
miR-372.10
4.2 Induction of reprogramming towards
iPSCs using miRNAs without stemness
factors
Recently, a non-transcription factor-mediated methodology using
miRNAs to reset mouse embryonic fibroblasts into a pluripotent
state has been reported.6 By transducing the miR-302/367 cluster,
Figure 2 Role of miRNAs in self-renewal and differentiation of pluripotent stem cells and in the differentiation of stem/progenitor cells into car-
diovascular lineage cells. Various miRNAs promote embryonic stem cell (ESC) differentiation, mostly by targeting stemness factors. In contrast, the
miR-290–295 cluster inhibits ESC differentiation. A subset of the miR-290–295 cluster (miR-291a-3p, miR-291b-3p, miR-294, and miR-295) plus
miR-302 are termed embryonic stem cell-specific cell cycle-regulating miRNAs (ESCCs) because they promote cell cycle progression in ESCs.
These miRNAs have also been used to increase efficacy of induced pluripotent stem cell (iPSC) formation. Furthermore, several miRNAs play an
important role in cardiovascular cell lineage differentiation and in the regulation of the phenotype of these cells. CM, cardiomyocyte; EC, endothelial
cell; VSMC, vascular smooth muscle cell.
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as well as the histone deacetylase inhibitor valproic acid (VPA), into
mouse embryonic fibroblasts, an increased efficacy of iPSC formation
was observed in comparison with transduction using stemness factors
(with VPA).6
Moreover, it has been shown that it is possible to reprogramme
cells to pluripotency without viral transfection by direct transfection
of mature miRNAs (miR-200c, miR-302s, and miR-369s family
members) into adipose stromal cells.9 However, the efficacy of dedif-
ferentiation was reduced in comparison with the viral transfection
procedures, especially in human dermal fibroblasts.9
The above studies demonstrate that miRNAs are strongly involved
in the regulation of pluripotency and differentiation of stem cells.
Lineage commitment steps are frequently regulated by multiple
miRNAs. Targeting miRNAs has therefore become an interesting
novel approach to modulate stem cell differentiation. A further
refined understanding of these miRNA-regulated pathways will lead
to novel tools to guide stem cell differentiation and function that is
particularly important for regenerative medicine. Moreover, direct re-
programming of adult fibroblasts into induced cardiomyocytes has re-
cently been reported,43 and it will be very interesting to see whether
this can also be enhanced or even achieved alone by targeting or
introduction of miRNAs.
5. MicroRNAs regulating vascular
smooth muscle cell differentiation
and phenotype
5.1 Vascular smooth muscle cell-specific
knockout of Dicer reveals a critical role of
miRNAs in vascular smooth muscle cell
differentiation
Recently, the role of miRNAs in differentiation and function of vascu-
lar smooth muscle cells (VSMCs) has been elucidated by generating a
VSMC-specific Dicer knockout mouse. Mutant mice died between
embryonic day 16 and 17 due to extensive haemorrhage and a
thinned wall of the aorta caused by a decreased proliferation of
VSMCs.44 Furthermore, a loss of contractile function and differenti-
ation of VSMCs could be observed, whereas transfection with
mimic miR-145 could partly rescue the impaired contractile function
and differentiation of VSMCs.44
5.2 miR-143 and miR-145 regulate VSMC
differentiation and phenotype
miR-143 and miR-145 are co-transcribed and are crucial for the fate
of VSMCs, regulating their differentiation, phenotype, and function.29
These miRNAs are co-transcribed and are controlled by Nkx2-5
(NK2 transcription factor related, locus 5) and the serum response
factor with its co-activator myocardin. miR-143 promotes VSCM
differentiation by repressing Elk-1,29 thereby preventing Elk-1-
dependent suppression of VSMC differentiation marker gene
expression.45 The potent properties of miR-145 to promote VSMC
differentiation were underlined by the observation that overexpres-
sion of miR-145 in neural crest stem cells resulted in differentiation
towards VSMCs in vitro.29 Mice lacking either miR-143 or miR-145,
or both express a less differentiated VSMC phenotype, indicating
that miR-143/145 modulate the fine-tuning of the plasticity of
VSMCs.46 Consistently, a decrease of contractile VSMCs and an accu-
mulation of synthetic VSMCs were found in the aorta and the thinned
femoral artery in another study examining a miR-143/miR-145 knock-
out mouse model.47 Moreover, agonist-mediated contractility in ar-
terial rings and blood pressure in vivo were reduced in miR-143/145
knockout mice.47
Inducible depletion of smooth muscle cell-specific Dicer in adult
mice led to a similar, although substantially more severe phenotype
as observed in miR-143/135 knockout mice, suggesting that additional
miRNAs are involved in maintaining post-natal VSMCs in a differen-
tiated state.48
5.3 miR-1 regulates VSMC differentiation
Recently, miR-1, which mediates cardiac muscle differentiation after
activation of myocardin, was shown to be involved in the differenti-
ation process of VSMCs.49,50 Overexpression of myocardin in
human VSMCs induces miR-1 and represses proliferation. This
process can be reversed by inhibition of miR-1.49 Furthermore, ESC
differentiation into VSMCs depends on miR-1. Expression of miR-1
was increased during differentiation of ESCs into VSMCs, whereas
inhibition of miR-1 repressed VSMC differentiation.50 miR-1 shares
an identical target with miR-145, the transcription factor Klf4.50
5.4 miR-221 and miR-222 regulate VSMC
phenotype
miR-221 and miR-222 target the cyclin-dependent kinase inhibitors,
p27 and p57, in VSMCs, thereby promoting cell cycle progression
and proliferation of these cells.51,52 Notably, knockdown of miR-221
and miR-222 suppressed VSMC proliferation in vivo and neointimal
lesion formation after carotid angioplasty,52,53 and these miRNAs
may therefore provide a potential therapeutic target to suppress for-
mation of neointima.51,52
6. MicroRNAs regulate vascular
integrity, endothelial cell
proliferation, and function
6.1 Dicer knockdown reveals critical role of
miRNAs in vascular development and
endothelial cell functions
SeveralmiRNAs have been identified to play an important role in vascular
growth, endothelial cell differentiation, proliferation, and functions. First
attempts to gain insight into the role of miRNAs in vascular develop-
ment/angiogenesis were made by engineering vertebrates lacking
Dicer.20 Dicer deficiency resulted in lethality in early development.34,53
Morphological analysis revealed less developed blood vessels in
embryos and fewer blood vessels in yolk sacs, suggesting that compro-
mised vessel formation/maintenance is leading to embryonic lethality.53
Consistent with this observation, mice with a hypomorphic Dicer
expression are infertile owing to impaired angiogenesis in the corpus
luteum.54 Moreover, a reduction of endothelial miRNAs by
Cre-dependent knockout of Dicer in endothlial cells resulted in impaired
angiogenesis in distinct models of post-natal angiogenesis.55
Subsequently, in vitro studies using Dicer-deficient endothelial cells
were performed. Silencing of Dicer in endothelial cells caused an im-
pairment of capillary sprouting, tube formation, and migration cap-
acity.56,57 This was, at least in part, related to down-regulation of
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pro-angiogenic miRNAs, i.e. let-7f and miR-27b, and subsequently an
increased expression of several anti-angiogenic factors.56,57
6.2 miR-126 regulates vascular integrity,
endothelial cell proliferation, and
neovascularization
The most abundant miRNA in CD31+ cells is miR-126.58
Morpholino-induced knockdown of miR-126 in zebrafish caused com-
promised vascular integrity and led to haemorrhages.58 Likewise,
defects in vascular maintenance were also shown in mice lacking
miR-126.59 Forty per cent of miR-126-deficient mice died embryoni-
cally or perinatally owing to defects in endothelial cell proliferation,
migration, and angiogenesis causing leaky vessels and haemorrhages.59
The surviving subset of mutant mice had a markedly increased mortal-
ity and reduced infarct borderzone neovascularization after myocar-
dial infarction.59 In summary, miR-126 is important for maintaining
vessel integrity during embryogenesis. This was further highlighted
in a study investigating aortic arch development in zebrafish, where
blood flow activated miR-126, which in turn enhanced vascular endo-
thelial growth factor signalling, thereby facilitating angiogenic sprout-
ing.60 However, miR-126 overexpression in ESCs failed to
up-regulate endothelial cell-specific markers in vitro, hence it is not suf-
ficient to induce endothelial lineage commitment in ESCs.58
6.3 miR-17-92 cluster regulates
neovascularization
As first shown in several studies in the oncology field, the miR-17-92
cluster, which is induced by the transcription factor c-Myc, regulates
distinct angiogenic functions.61,62 miR-92a, a member of the
miR-17-92 cluster, exerts antiangiogenic functions.63 Antagomir-based
silencing of miR-92a increases infarct borderzone neovascularization
after myocardial infarction.63 miR-17, miR-18a, miR-19a, and
miR-20a inhibit angiogenic activity of mature endothelial cells in
vitro, and knockdown of miR-17 and miR-20a increased vessel forma-
tion as observed in a matrigel plug assay in vivo.64 In contrast,
miR-17-5p, miR-18a, and miR-20a promote proliferation and cord for-
mation in Dicer-deficient human endothelial cells55 and enhance neo-
vascularization in tumour cells transduced with the miR-17-92
cluster,65 indicating that the regulatory mechanisms of the
miR-17-92 cluster differ in distinct tissues and are dependent on the
cellular context. Therefore, the effect of miRNAs from the 17-92
cluster differs for ischaemia-induced and tumour-associated angiogen-
esis, which is important if one considers these miRNAs as potential
therapeutic targets.
7. MicroRNAs and cardiomyocyte
differentiation
7.1 miR-1 and miR-133 control
cardiomyocyte differentiation
miR-1 and miR-133 are highly expressed in cardiac and skeletal muscle
cells, and their precursors belong to the same transcriptional unit and
play a critical role in myogenesis.66–69 miR-1, consisting of two
miRNA genes (miR-1-1 and miR-1-2) is co-transcribed with two
(miR-133a-2 and miR-133a-1) of the three existing miR-133
genes.66,69 These miRNAs are induced by the muscle differentiation
factors serum response factor, Mef2, and myocardin.66,70
miR-1 (and to a lesser extent miR-133) promotes mesodermal pro-
genitor formation and suppresses non-muscle gene expression in
mouse and human ESCs.71 The miR-1-dependent adoption of a myo-
genic phenotype is supported by the repression of Hdac4, which
negatively regulates Mef2, an essential transcription factor for the dif-
ferentiation pathway of muscle cells.70,72 Furthermore, miR-1 down-
regulates Notch ligand Delta-like 1, which is involved in cardiomyo-
cyte differentiation of ESCs and cardiac progenitor cell division.71
miR-1 also modulates the fine-tuning of cell polarity.73 Fly embryos
deficient in dmiR-1 had misaligned cardioblasts.73
In vivo, deletion of dmiR-1, the single orthologue of miR-1 in Dros-
ophila, is lethal due to a loss of muscle differentiation.67 miR-1-2
mutant mice revealed ventricle septum defects, cardiac hyperplasia,
and abnormal conduction.74 In this study, miR-1-1, the second
member of the miR-1 family, could not compensate for the loss of
its redundant miR-1-2.74 Overexpression of dmiR-1 decreased
cardiac cell number,67 while cardiac-specific excess of miR-1 in mice
decreased proliferation by targeting Hand2, a transcription factor
regulating ventricular cardiomyocyte expansion.66
miR-133 plays a distinct role after mesodermal differentiation. In
contrast to miR-1, miR-133 represses cardiac markers, promotes pro-
liferation of myoblasts, and inhibits differentiation through repression
of serum response factor.71 Depletion of the miR-133 family resulted
in defects of cardiac morphogenesis and increased proliferation of
cardiomyocytes, whereas single depletion resulted in a normal
phenotype.75
7.2 miR-17-92 cluster regulates cardiac
development
The miR-17-92 cluster contributes to regulation of heart develop-
ment, as indicated by ventricular septal defects of the hearts in a
loss-of-function model.76 Furthermore, miR-92 controls endoderm
development.77 Overexpression of miR-92 in zebrafish results in a
suppression of endoderm formation, which leads to cardia bifida.77
7.3 miR-499 promotes cardiomyocyte
differentiation
During cardiomyocyte differentiation of human cardiomyocyte pro-
genitor cells,78 human cardiac stem cells,79 and human ESCs,80
miR-499 is highly up-regulated. Overexpression of miR-499 in
human cardiomyocyte progenitor cells indirectly promotes cardiac
muscle differentiation by targeting sex determining region Y-box 6
(Sox6) and regulator of differentiation 1 (Rod1) in vitro.78,79 Further-
more, overexpression of miR-499 in hESCs and human cardiomyocyte
progenitor cells up-regulated cardiac marker expression, suggesting a
role for miR-499 to control cardiomyocyte cell fate.78,80 However, in
adult mice cardiac miR-499 overexpression resulted in cellular cardiac
hypertrophy and cardiac dysfunction.81
8. MicroRNA alterations in human
cardiovascular disease
Dysregulated expression of miRNAs has been observed in human car-
diovascular disease, including altered regulation in progenitor cells.82
miRNA tissue profiling approaches in cardiomyopathies83 and in pro-
genitor cells84 revealed an altered regulation of miRNAs in different
cardiovascular disease states. Subsequently, circulating human
miRNA expression profiles in plasma samples were investigated in
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distinct cardiovascular diseases, such as stable coronary artery
disease85 and essential hypertension,86 as well as in patients with car-
diovascular risk factors, such as diabetes mellitus.87,88
Recently, miRNAs have been implicated in the functional cardiovas-
cular repair capacity of progenitor cells (Table 1). Thus, differential
miRNA regulation may play a role in cardiovascular disease both by
altering the repair potential of progenitor cells, as well as by impacting
on the function and phenotype of differentiated cells. Here we will
discuss in particular the miRNAs that may also play a role in progeni-
tor cells.
9. MicroRNA regulation in early
endothelial progenitor cells in
cardiovascular disease
Early endothelial progenitor cells (EPCs) have been suggested to
promote endothelial cell growth (largely in a paracrine manner) and
may thereby promote endothelial repair responses and improve
cardiac function. As described in detail below, several recent studies
have described alterations in miRNAs in early EPCs derived from
patients with cardiovascular disease, which may critically limit the en-
dogenous repair response.
9.1 miR-21 is increased in early EPCs in
coronary artery disease
In circulating EPCs, miR-21 has been reported to be up-regulated after
treatment with asymmetrical dimethylarginine.84 Expression of
miR-21 was increased in early EPCs from patients with coronary
artery disease.84 Moreover, overexpression of miR-21 in early EPCs
has been shown to inhibit their migratory capacity through repression
of superoxide dismutase 2, a key protection protein against oxidative
damage, and the endogenous mitogen-activated protein kinase inhibi-
tor, sprouty-2.84
9.2 miR-221 and miR-222 are increased in
early EPCs in coronary artery disease
miR-221/222 levels have been observed to be increased in early EPCs
derived from patients with coronary artery disease in comparison
with healthy subjects and were inversely correlated with EPC
number in these patients.89 After treatment with atorvastatin,
miRNA-221/222 expression decreased and early EPC number
increased in patients with coronary artery disease, but no causal rela-
tionship has been examined.89 miR-221 and miR-222 are also
expressed in VSMCs and endothelial cells. Endothelial cells overex-
pressing miR-222 showed a diminished proliferation and vessel forma-
tion in matrigel plugs.90
In VSMCs, platelet-derived growth factor, a major growth factor to
promote neointimal formation, induces miR-221/222 expression in
vitro.52 Knockdown of miR-221/222 decreases cell proliferation in cul-
tured VSMCs, as well as neointimal formation in balloon-injured rat
arteries.52
9.3 miR-126 and miR-130a are reduced in
early EPCs in chronic heart failure
Early EPCs from patients with chronic heart failure due to ischaemic
cardiomyopathy showed a markedly reduced expression of miR-126
in comparison with early EPCs from healthy subjects, and the in vivo
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Table 1 MicroRNAs (miRNAs) differentially regulated in early endothelial progenitor cells or miRNAs mediating
preconditioning and regulating viability of stem/progenitor cells
Cell type Differentially expressed
miRNA
Disease/modulator Targets Function Reference
A: miRNA regulation in early endothelial progenitor cells
Early endothelial progenitor
cells
miR-21  CAD/ADMA SOD2 ; SPRY2

Migration 
ROS formation 
84
Early endothelial progenitor
cells
miR-221/222  CAD Early EPC number  89
Early endothelial progenitor
cells
miR-126  CHF Spred1  Angiogenesis  91
Early endothelial progenitor
cells
miR-130a  CHF HoxA5  Angiogenesis  91
Early endothelial progenitor
cells
miR-34a  miRNA-overexpression Sirt1  Senescence 
Angiogenesis 
95
B: miRNAs mediating preconditioning and regulating viability of stem/progenitor cells
Mesenchymal stem cells miR-210  IP Flash/Casp8ap2

Apoptosis  100
Skeletal myoblast miR-21  PP (diazoxide) Apoptosis  96
Mesenchymal stem cells miR-146a PP (diazoxide) Fas (CD95)  Apoptosis  98
Cardiomyocyte progenitor
cells
miR-155  H2O2 RIP1  Necrosis  99
Cardiac progenitor cells miR-21, miR-24, miR-221 
(cocktail)
miRNA overexpression Bim  Viability  101
ADMA, asymmetrical dimethylarginine; Bim, Bcl2l11 (Bcl-2 protein family); CAD, coronary artery disease; CHF, chronic heart failure; EPC, endothelial progenitor cell; Flash/Casp8ap2,
FLICE-associated huge protein/caspase-8-associated protein-2; IP, ischaemic preconditioning; PP, pharmacological preconditioning; RIP1, receptor interacting protein 1; Sirt1, Silent
information regulator 1; ROS, reactive oxygen species; SOD2, superoxide dismutase type II; Spred1, Sprouty-related EVH-1 domain containing-1; SPRY2, Sprouty2.
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cardiac repair capacity of EPCs from healthy subjects was markedly
reduced after anti-miR-126 transfection.91 Moreover, a reduced ex-
pression of miR-130a was observed in early EPCs from patients
with chronic heart failure.91 This miRNA is known to promote angio-
genesis by targeting the homeobox genes GAX and HOXA5 in endo-
thelial cells.92
The role of miR-126 in ischaemia-induced angiogenesis has been
further shown by an antagomir-based silencing of miR-126 in a hind-
limb ischaemia model, in which capillary vessel formation was
reduced.93
9.4 miR-34a limits pro-angiogenic capacity
of early EPCs
miR-34a has been suggested as an anti-angiogenic and pro-apoptotic
miRNA expressed in early EPCs, and has been shown to target
silent information regulator 1 (Sirt1) in colorectal carcinoma cells.94
Sirt1 is a regulator of apoptosis, the cell cycle, and senescence and
acts as a mediator of angiogenesis in endothelial cells. Introduction
of mimic miR-34a into rat early EPCs inhibited angiogenesis and
induced senescence in vitro.95 This was suggested to be mediated by
Sirt1 targeting and partly by up-regulation of a downstream target
of Sirt1, forkhead box O transcription factor 1.95
10. MicroRNAs mediate
preconditioning and regulate
viability of stem/progenitor cells
Recent studies, as described below, have explored the role of
miRNAs in mediating preconditioning effects on stem/progenitor
cells. These findings may provide interesting novel opportunities for
optimization of cell-based treatment approaches for cardiac repair.
10.1 miR-21 exerts cytoprotective effects in
skeletal myoblasts
In skeletal myoblasts, miR-21 was up-regulated after pharmacological
preconditioning with diazoxide.96 The observed cytoprotective
effects (with respect to oxidative stress challenge) were reduced
after anti-miR-21 treatment, suggesting a critical role of miR-21 in
this process.96 miR-21 was also up-regulated in left ventricles of rats
after ischaemic preconditioning in vivo and has been proposed to
exert anti-apoptotic effects through inhibition of programmed cell
death 4.97
10.2 miR-146a protects mesenchymal stem
cells from apoptosis
Preconditioning of mesenchymal stem cells with diazoxide prevented
these cells from apoptosis through a nuclear factor-kB-dependent in-
duction of miR-146a in vitro.98 Up-regulation of miR-146a has cytopro-
tective effects by repression of Fas (CD 95), a tumour necrosis factor
receptor family member, which is required for cell death
programming.98
10.3 miR-155 may improve survival of
cardiomyocyte progenitor cells
miR-155 is up-regulated in human cardiomyocyte progenitor cells
after exposure to hydrogen peroxide and has been suggested to
improve their survival and inhibit necrosis through repression of
receptor interacting protein 1, a death domain receptor-associated
protein.99
10.4 miR-210 improves survival of
transplanted mesenchymal stem cells
in the heart
Ischaemic preconditioning of mesenchymal stem cells up-regulated
miR-210 expression in a hypoxia-inducible factor-1a-dependent
fashion and improved their survival after engraftment in the rat infarcted
heart.100 This was mediated by targeting FLICE-associated huge
protein/caspase-8-associated protein-2, a pro-apoptotic regulator.100
10.5 miRNA cocktail (miR-21, miR-24, and
miR-221) improves viability of transplanted
cardiac progenitor cells
As miRNAs can improve the functional behaviour of progenitor cells,
transfection with multiple miRNAs is an emerging approach in order
to target the same deleterious transcript more efficiently or to
repress multiple mRNAs in order to influence a pathophysiological
process. In this respect, Hu et al. recently used an miRNA cocktail
consisting of miR-21, miR-24, and miR-221 to transfect mouse
cardiac progenitor cells, thereby showing that the viability of the
transfected cells is enhanced after intramyocardial delivery, accom-
panied by an enhanced cardiac function after myocardial infarction.101
11. Conclusions
MicroRNAs have been identified as critical regulators of embryonic
stem cell self-renewal and differentiation. Several miRNAs have also
been reported to promote iPSC reprogramming, which is particularly
important for regenerative medicine. Specific miRNAs have been sug-
gested to play a critical role in the differentiation of cardiovascular
lineage cells, i.e. in vascular smooth muscle, endothelial cell, and car-
diomyocyte differentiation and function.
Notably, miRNAs are differentially regulated in different cardiovas-
cular diseases, including miRNAs expressed in stem/progenitor cells.
Altered expression profiles in circulating progenitor or resident
tissue stem/progenitor cells may impair the endogenous cardiovascu-
lar repair capacity. As miRNA-targeted therapies are entering the clin-
ical arena, a detailed understanding of the role of miRNAs in stem/
progenitor cell differentiation and functions, as well as the alterations
in cardiovascular disease, is therefore required. A further understand-
ing of the role of specific miRNAs in regulating or limiting endogenous
cardiovascular repair responses involving stem/progenitor cells and
cardiovascular lineage differentiation may lead to interesting novel
therapeutic strategies to promote cardiovascular repair.
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